Concerns about anaesthesia-related neurological injury in young children have been increasing among parents, health-care providers, and regulatory organisations. These concerns were first prompted by animal studies that showed accelerated apoptosis and neuronal death after exposure to general anaesthetic drugs. Most commonly used general anaesthetic drugs have since been found to cause pervasive adverse neurological effects in vitro and in immature animals, including non-human primates. This issue gained widespread prominence in 2017, when the US Food and Drug Administration issued a safety communication stating that the use of general anaesthetic drugs “for lengthy periods of time or over multiple surgeries or procedures may negatively affect brain development in children younger than 3 years”. Subsequently, warnings were added to the labels for these medicines.
- General anaesthesia during infancy reduces white matter micro-organisation in developing rhesus monkeys British Journal of Anaesthesia
- A synthetic peptide rescues rat cortical neurons from anesthetic-induced cell death, perturbation of growth and synaptic assembly
- The Effects of Hesperidin on Neuronal Apoptosis and Cognitive Impairment in the Sevoflurane Anesthetized Rat are Mediated Through the PI3/Akt/PTEN and Nuclear Factor-κB (NF-κB) Signaling Pathways
- Dexmedetomidine and Clonidine Attenuate Sevoflurane-Induced Tau Phosphorylation and Cognitive Impairment in Young Mice via α-2 Adrenergic Receptor
- Regulation of CRMP2 by Cdk5 and GSK-3β participates in sevoflurane-induced dendritic development abnormalities and cognitive dysfunction in developing rats